Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial | MicrobiomeTrials← Back to trialsNCT07726693
Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-07-15Est. Completion: 2030-10-31
Enrollment target: 1,142 participants Other microbiome trials you might be interested in
Hematopoietic Stem Cell Transplant
Background:
Hematopoietic stem cell transplant (HSCT) is a common treatment for many cancers and other illnesses. But m…
Bethesda, United StatesEst. completion Jun 30, 2031
Chronic Hepatitis B
Background:
Chronic hepatitis B virus (HBV) infection affects 292 million people worldwide; 887,000 die each year from …
Bethesda, United StatesEst. completion Feb 29, 2028
Non-Alcoholic Fatty Liver DiseaseSteatohepatitis, NonalcoholicLiver Fibroses
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent condition, and when fatty liver is associated with infla…
Reggio Emilia, ItalyCompleted Jun 1, 2022